Health & Biotech Clinical Trials 101: How to spot a clinical trial with a strong chance of getting a drug to market October 18, 2022 Part three of our breakdown on understanding the clinical trials process for investors looks at getting a drug to market. ASX Health Stocks: Patrys crosses brain barrier, opens up possibilities for its deoxymab antibody October 17, 2022 Patrys (ASX:PAB) surged 15% after announcing that its deoxymab antibody, PAT-DX3, has crossed the blood brain barrier in healthy animals. ASX Health Stocks: Canada says yes to Telix, while EBR keeps market in suspense over pending announcement October 14, 2022 EBR Systems (ASX:EBR) has asked for its shares to be temporarily suspended this morning, pending an announcement. Incannex jumps another hurdle to advance to Phase 2 clinical trials of its anti-inflammatory drug October 14, 2022 Special Report: After completing patient dosing in its Phase 1 clinical trial of anti-inflammatory IHL-675A, Incannex Healthcare has advanced to… Clinical Trials 101: The critical review process and getting drugs to market October 14, 2022 Part two of our breakdown on understanding the clinical trials process for investors looks at reviewing clinical trials. ASX Biotech Stocks: This brain training app could catch dementia early and Brainchip nabs more patents October 13, 2022 This new brain training app could catch dementia in its early stages BrainChip acquires JAST learning rule technology - including… Exopharm identifies two new lead programs as exosomes gain prominence in gene therapy October 13, 2022 Special Report: Exopharm’s technology has put the company in a leadership-position in both naïve exosomes and engineered exosomes as it… Weed Week: US looks to decriminalise cannabis and Victoria Greens say legal weed could mean $1.21bn in revenue October 13, 2022 The US could potentially reclassify cannabis, and the Victorian Greens want to legalise and tax the drug at 30%. ASX Health Stocks: Cynata races ahead after getting green light for diabetic foot ulcer clinical trial October 12, 2022 Cynata Therapeutics (ASX:CYP) announced that an independent review of Cynata’s diabetic foot ulcer (DFU) clinical trial has been completed. Clinical Trials 101: How to know your placebos from blinded studies October 12, 2022 Understanding the clinical trial process is crucial for investing in biotechnology companies so here's part one of our breakdown. Next» « Previous